BioNTech SE (NASDAQ:BNTX) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 39.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,355 shares of the company's stock after purchasing an additional 53,319 shares during the period. Charles Schwab Investment Management Inc. owned about 0.08% of BioNTech worth $21,349,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. FMR LLC lifted its stake in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after acquiring an additional 5,598,190 shares during the period. Flossbach Von Storch SE lifted its stake in BioNTech by 1.1% in the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after acquiring an additional 47,236 shares during the period. Fred Alger Management LLC purchased a new stake in shares of BioNTech during the third quarter valued at about $59,485,000. abrdn plc lifted its position in shares of BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after buying an additional 159,676 shares during the last quarter. Finally, Braidwell LP purchased a new stake in shares of BioNTech during the third quarter valued at about $29,425,000. 15.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. BMO Capital Markets increased their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an "overweight" rating and a $170.00 price target for the company. Citigroup assumed coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 price target for the company. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research report on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $143.73.

Remove Ads

BioNTech Stock Performance

NASDAQ:BNTX traded down $0.85 during midday trading on Friday, hitting $95.38. The company's stock had a trading volume of 787,017 shares, compared to its average volume of 783,641. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm's 50 day moving average is $113.02 and its 200-day moving average is $113.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market cap of $22.89 billion, a P/E ratio of -45.42 and a beta of 0.30.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the company earned $1.90 EPS. BioNTech's quarterly revenue was down 19.5% on a year-over-year basis. Equities analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.